Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/l

AIDS

Volumn 16, Issue 10, 2002, Pages 1371-1381

  Opravil, Milos ^a   Ledergerber, Bruno ^a   Furrer, Hansjakob ^b   Hirschel, Bernard ^c   Imhof, Alexander ^a   Gallant, Serge ^d   Wagels, Thomas ^f   Bernasconi, Enos ^g   Meienberg, Fabian ^e   Rickenbach, Martin ^h   Weber, Rainer ^h  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^g Hospital of Lugano   (Switzerland)

^h University Hospital ^*

Author keywords

Asymptomatic HIV infection; CD4 cell count; Clinical progression; Cohort study; Initiation of highly active antiretroviral therapy

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; GASTROINTESTINAL TOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LEUKOCYTE COUNT; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INFECTION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; IMMUNOLOGY; PROPORTIONAL HAZARDS MODEL; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COMPARATIVE STUDY; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMAN; MALE; PROPORTIONAL HAZARDS MODELS; SUPPORT, NON-U.S. GOV'T; TREATMENT OUTCOME; VIRAL LOAD; HUMANS;

EID: 0037024757     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200207050-00009     Document Type: Article

References (50)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
3. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997
4. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
5. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
6. 3
7. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection
8. Immune control of HIV-1 after early treatment of acute infection
9. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes
10. Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy
11. Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: A randomized trial of double versus triple therapy. Swiss HIV Cohort Study
12. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection
13. Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression
14. Viral load and heterosexual transmission of human immunodeficiency virus type 1
15. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
16. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving longterm nucleoside analogue therapy
17. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study
18. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
19. Antiretroviral drugs
20. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: Comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups
21. Clinical epidemiology and research on HIV infection in Switzerland: The Swiss HIV Cohort Study 1988-2000
22. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
23. Partial residuals for the proportional hazards regression model
24. Estimating causal effects from large data sets using propensity scores
25. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group
26. An assessment of clinically useful measures of the consequences of treatment
27. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases
28. The effects on survival of early treatment of human immunodeficiency virus infection
29. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection
30. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group
31. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group
32. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: The Swiss HIV Cohort Study
33. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: Results from the EuroSIDA study
34. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy
35. Late initiation of antiretroviral therapy (at CD4+ lymphocyte count <200 cells/mL) is associated with increased risk of death
36. CD4+ lymphocyte level is better than HIV-1 plasma viral load in determining when to initiate HAART
37. Prognosis of HIV-1 infected drug naive patients starting potent antiretroviral therapy: Multicohort analysis of 12040 patients
38. The cost effectiveness of combination antiretroviral therapy for HIV disease
39. The number needed to treat: A clinically useful measure of treatment effect
40. Aspirin for primary prevention of coronary heart disease: Safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials
41. Treatment comparisons in HIV infection: The benefits and limitations of observational cohort studies
42. Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone
43. Reasons for modification and discontinuation of antiretrovirals: Results from a single treatment centre
44. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team
45. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial
46. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA
47. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-Year prospective follow-up of a multicenter, randomized, controlled study
48. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection
49. Are HIV-infected patients with rapid CD4 cell decline a subgroup who benefit from early antiretroviral therapy?